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UNIFESP, São Paulo, Brazil; and 3Clinical Analysis Laboratory of Faculdade de Medicina do ABC, Santo André, BrazilIntroduction: Diabetic nephropathy is associated with speciﬁc histological changes. Early detection of
poor glomerular and tubular function can be achieved with biomarkers of diabetes. The aim of this study
was to evaluate the accuracy of kidney dysfunction biomarkers in type 2 diabetes (T2D).
Methods: Patients with T2D were grouped according to their glycated hemoglobin level. Patients’ urine
and blood samples were taken to measure cystatin C (CysC), neutrophil gelatinase-associated lipocalin,
beta-trace protein levels, and the ﬁrst morning void albumin-to-creatinine ratio. Patients in the end stage of
renal disease or receiving dialysis were not included. Receiver operating characteristic curves were
generated, and the areas under the curve were compared with the performance of the biomarkers used to
evaluate kidney dysfunction in T2D.
Results: Ninety patients with T2D were chosen. CysC was positively correlated with creatinine (P < 0.001),
estimated glomerular ﬁltration rate (P < 0.001), and urinary beta-trace protein (P ¼ 0.01). The area under
the curve was 0.635 for CysC, 0.621 for serum neutrophil gelatinase-associated lipocalin, and 0.660 for
the albumin-to-creatinine ratio. A crude logistic regression model showed a positive association between
serum CysC (P ¼ 0.01) and serum neutrophil gelatinase-associated lipocalin (P < 0.001). A linear
regression model showed a positive association between serum CysC, creatinine, and estimated
glomerular ﬁltration rate (P < 0.001) but did not show a positive association with glycated hemoglobin
(P ¼ 0.892).
Discussion: Neutrophil gelatinase-associated lipocalin and serum CysC were positively associated with
the presence of renal dysfunction and had better performance on receiver operating characteristic analysis
than the other markers evaluated in patients with T2D without kidney dysfunction.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).D iabetic nephropathy is a syndrome characterizedby the presence of macroalbuminuria, a slow and
progressive decline in glomerular ﬁltration rate (GFR),
elevated blood pressure, and cardiovascular mortality.1
Renal diabetes histopathologic changes include
thickening of the glomerular basement membrane,
mesangial matrix expansion, hyalinosis, and thickening
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International Reports (2016) -, -–-described by Kimmestiel and Wilson in 1936 is char-
acterized by the diffused and intercapillary prolifera-
tion of the mesangial matrix or nodular sclerosis. These
changes are very common in type 1 diabetes, but for
type 2 diabetes (T2D), there is a lack of scientiﬁc
research comprehensively showing the progression of
kidney disease; however, the changes are thought to be
similar.1,2
Glomerular mesangial matrix expansion can accel-
erate the progression of diabetes by approximately
15 years, and its degree of increase is directly pro-
portional to the extent of the decreases in GFR and the
area of capillary ﬁltration. Thus, the presence of
albuminuria is closely related to the existence of1
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mesangial expansion.3
In an animal model using mice, an increase in kidney
size above hyperﬁltration was attributed to high net
reabsorption in the proximal convoluted tubule,
causing reduced tubular hydrostatic pressure and
inhibiting ﬂuid secretion at the end portion of the
segment.4
An ideal renal function marker must have constant
production, rapid diffusion in the extracellular space,
free clearance, an absence of resorption and/or tubular
secretion, an absence of deletion or extrarenal degra-
dation, and the existence of accurate and reproducible
tests without interference from other components.5
Many markers have been used to predict early-stage
renal dysfunction in diabetic patients; however, the
reference levels have not been established for these
markers. The presence of microalbuminuria is a sign of
the presence of diabetic kidney disease and marks the
beginning of more intense therapy.
Thus, the primary objective of this study was to
evaluate the accuracy of neutrophil gelatinase-
associated lipocalin (NGAL) and serum cystatin C
(CysC) as markers of renal dysfunction in T2D.
The secondary objectives were to evaluate the
performance of other urinary and inﬂammatory
markers and to understand their interaction in
patients with T2D.
METHODS
Study Population
The study population consisted of patients who had
T2D for at least 5 years according to their medical re-
cords and were older than 21 years. The study was
approved by the ABC Medical School ethics committee,
and all individuals gave signed informed consent
before inclusion.
Ineligible patients were those with chronic kidney
disease with a cause other than T2D, those who were
receiving dialysis, those who had undergone hospital-
ization for any reason within 30 days before sample
collection, those who had cancer and were being
treated, those who had AIDS and were taking immu-
nosuppressive drugs, and those who had undergone
kidney or renal and pancreatic transplants.
Laboratory Measurements
GFR Valuation
The Modiﬁcation of Diet in Renal Disease simpliﬁed
equation was used to calculate the estimated GFR
(eGFR) in ml/min per 1.73 m2.6 Renal dysfunction
was deﬁned as eGFR < 60 ml/min per 1.73 m2 ac-
cording to the Kidney Disease: Improving Global Out-
comes chronic kidney disease deﬁnition.2Blood samples were taken to determine serum
creatinine, NGAL, and CysC levels as glomerular
markers of kidney function.
Serum creatininewasmeasured using the colorimetric
method. The NGAL concentrations and CysC were
determined using an automated enzyme-linked immu-
nosorbent assay (IBL International, Hombrechtikon,
Switzerland) with the aid of Labotech (Adaltis, Rome,
Italy) enzyme-linked immunosorbent assay equipment.
Tubular Function Evaluation
To evaluate the presence of tubular dysfunction, the
following urinary markers were measured: urinary
NGAL, CysC, urinary gene expression of beta-trace
protein (BTP), and urinary albumin-to-creatinine ratio
(ACR). The cutoff values used in determining the
normality of NGAL and CysC were deﬁned according
to each calibration reagent used. The ACR was
considered to be normal if its value was less than
30 mg/g; microalbuminuria was indicated by levels
between 30 and 300 mg/g, and macroalbuminuria was
indicated by levels above 300 mg/g.
Glycemic Control Evaluation
Glycemic control assessment was performed using the
values of fasting glucose and glycated hemoglobin
(HbA1c). Values above 140 mg/dl for glucose and above
7% for HbA1c were considered abnormal.
Inﬂammatory Proﬁle Evaluation
The inﬂammatory proﬁle of each patient was obtained
by measuring the serum levels of the following
markers: ultrasensitive C-reactive protein, interleukin-6,
tumor necrosis factor-a, homocysteine, serum beta-2
microglobulin (B2M), and 25-OH vitamin D. Measure-
ments were performed using the immunoenzymatic
method with chemiluminescence values determined
using Immulite 1000 equipment (Siemens, Erlange,
Germany).7 For each marker, the cutoff value was
deﬁned according to the guidelines of the kit.
Urinary Gene Expression of BTP
The urinary gene expression of BTP was determined by
plasma RNA isolation (initial amount, 1 mg). Synthesis
of the cDNA was performed using SSIII ﬁrst-strand
quantitative polymerase chain reaction (qPCR) Super-
mix (Invitrogen, cat no. 11752050; Carlsbad, CA, USA).
The BTP urinary gene expression was evaluated by
quantitative real-time reverse transcriptase-PCR. Spe-
ciﬁc primers for each selected gene were designed us-
ing Input Primer3 Blast program version 0.4.0.
Glyceraldehyde-3-phosphate dehydrogenase was
used as a reference gene to normalize the relative
expression of the target gene expression values. The
initial standardization of quantitative real-time reverse
transcriptase-PCR ampliﬁcations occurred in a ther-
mocycler: Applied Biosystems 7500 real-time PCRKidney International Reports (2016) -, -–-
Table 1. Demographics and baseline characteristics of the whole
study population
Variable
Group 1 (HbA1c < 7)
n [ 30
Group 2 (HbA1c ‡ 7)
n [ 60
Male (%) 40.00 53.30
Age (yr) 61.50 (9.80) 61.20 (9.68)
Ethnicity (%)
Caucasian 76.60 80.00
Black 33.40 20.00
Hypertension (%) 90.00 85.00
BMI 32.00 (4.80) 29.60 (4.98)
Urea (mg/dl) 41.00 (20.90) 48.40 (28.40)
Creatinine (mg/dl) 1.07 (0.41) 1.22 (0.64)
eGFR (ml/min per
1.73 m2)
83.80 (35.80) 76.70 (36.12)
sCys C (ng/ml) 3.42 (1.44) 3.94 (1.55)
uCys C (ng/ml) 0.50 (0.10–0.50) 0.50 (0.07–0.50)
sNGAL (ng/ml) 0.80 (0.37–1.07) 0.80 (0.40–1.08)
uNGAL (ng/ml) 0.01 (0.01–0.37) 0.01 (0.01–0.37)
uBTP 0.10 (0.10–3.13) 0.10 (0.10–3.04)
ACR (mg/g) 36.10 (9.82–103.60) 38.30 (10.10–104.00)
HbA1c (%) 6.21 (2.02) 9.20 (4.24)
TNF-a (pg/ml) 9.82 (4.83) 9.09 (4.84)
IL6 (pg/ml) 2.00 (2.00–3.08) 2.00 (2.00–3.08)
CRP (mg/l) 5.15 (1.93–11.70) 5.15 (1.82–11.02)
Homocisteine
(mmol/l)
11.58 (6.00) 12.30 (5.86)
B2M (ng/ml) 2365.00 (1786.50–3028.50) 2439.00 (1850.25–3049.00)
Vitamin D (ng/ml) 17.46 (8.11–22.16) 17.55 (8.11–21.71)
Data presented as mean  SD and median with interquartile ranges.
ACR, albumin-to-creatinine ratio; B2M, beta 2 microglobulin; BMI, body mass index;
BTP, beta-trace protein; CRP, ultrasensitive C-reactive protein; CysC, cystatin C; eGFR,
estimated glomerular ﬁltration rate; HbA1c: glycated hemoglobin; IL6, interleukin 6;
NGAL, neutrophil gelatinase-associated lipocalin.
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The ﬁnal volume was 15 ml, which contained 1 SYBR
Green mix (QuantiTect SYBR Green PCR kit, QIAGEN
Cat. No. 204 054), 10 pmol of each speciﬁc primer, and
2 ml of cDNA initially diluted 10. The initial cyclic
parameters consisted of a hot start step at 95 C for 15
seconds and 60 C for the primer sequence.
Statistical Analyses
The ability of the glomerular and tubular function
markers to discriminate between different levels of
eGFR impairment was assessed by receiver operating
characteristic (ROC) analysis. Renal dysfunction was
deﬁned as an eGFR equal to or less than 60 ml/min per
1.73 m2.
Multivariate analysis via logistic regression was used
to identify the covariates associated with the occur-
rence of renal dysfunction. Initially, univariate binary
logistic regression analyses were conducted to test the
association between each covariate and the variable
binary response. Then, the covariates with P < 0.05 in
the univariate regression analyses were considered in a
multiple logistic regression model. The ﬁnal model was
obtained following a manual backward stepwise elim-
ination process wherein models were examined for
indications of an inﬂuence attributable to the removed
nonsigniﬁcant variable.
When the assumption was not fulﬁlled, the quanti-
tative covariates in the logistic regression were
dichotomized for use by utilizing the optimal cutoff
point obtained from the ROC analysis. The presence of
multicollinearity was assessed by estimating the vari-
ance inﬂation factors. The calibration and discrimina-
tory ability of the ﬁnal multiple logistic regression
model were evaluated by the Hosmer-Lemeshow test
and ROC analysis, respectively.
Linear correlation analysis and comparison of the
quantitative variables between 2 groups were con-
ducted using Spearman’s correlation and the Mann-
Whitney test. Data normality was assessed using both
visual inspection of histograms and the Shapiro-Wilk
normality test. Quantitative variables were described
as medians and percentiles, and correlation coefﬁcients
were presented as 95% conﬁdence intervals.
All statistical analyses were performed using R
software (R Foundation, Austria). Statistical signiﬁ-
cance was evaluated at the 95% conﬁdence level
(P < 0.05).
RESULTS
Patients at the outpatient diabetic kidney setting of
ABC Medical School, Sao Paulo, Brazil, were included
sequentially during the years 2013–2015. They were
evaluated after giving their informed consent, resultingKidney International Reports (2016) -, -–-in the inclusion of 100 patients with T2D. Ten patients
had kidney disease with a cause other than diabetes
and were excluded, resulting in 90 patients in this
sample.
Table 1 shows the demographics of the sample.
Among the patients, the HbA1c was 6.21% for the
group with better glycemic control and 9.2% for
the group with worse glycemic control. Furthermore,
the average eGFR for both groups was greater than
60 ml/min per 1.73 m2, speciﬁcally 83.8 ml/min per
1.73 m2 for the group with HbA1c less than 7% and
76.7 ml/min per 1.73 m2 for the group with worse
glycemic control.
ROC Curves for the Various Biomarkers in
Patients With T2D
The performance of each tested marker was analyzed
by considering the change in renal function endpoint,
which is deﬁned by the eGFR calculated by the
simpliﬁed formula Modiﬁcation of Diet in Renal Disease
and the value of serum creatinine, which are shown in
Table 2.
The area under the curve (AUC) of serum CysC was
0.635. The ACR showed the best performance in
determining the presence of renal dysfunction in3
Table 2. Receiver operating characteristics curve values for the
biomarkers tested in patients with type 2 diabetes
Variable Sensitivity Speciﬁcity AUC (95% CI)
uNGAL 0.15 0.96 0.526 (0.42–0.64)
sNGAL 0.75 0.53 0.621 (0.51–0.71)
sCysC 0.37 0.88 0.635 (0.52–0.73)
uCysC 0.70 0.46 0.569 (0.44–0.69)
ACR 0.70 0.62 0.660 (0.53–0.78)
uBTP 0.85 0.35 0.567 (0.46–0.67)
ACR, albumin-to-creatinine ratio; AUC, area under the curve; BTP, beta-trace protein;
CI, conﬁdence interval; CysC, cystatin C; HbA1c, glycated hemoglobin; NGAL, neutrophil
gelatinase-associated lipocalin.
Table 4. Variables associated with worse kidney function in
patients with type 2 diabetes. Univariate and multivariate regression
models
Variables
Univariate Multivariate
OR 95% CI P OR 95% CI P
Age 1.05 1.00–1.10 0.030 1.06 0.99–1.14 0.080
Male 9.80 3.69–25.98 <0.001 14.85 3.34–65.93 <0.001
sNGAL 3.39 1.36–8.42 <0.001 3.53 0.80–15.46 0.090
sCysC 1.48 1.08–2.04 0.010 1.48 0.84–2.60 0.170
B2M 4.01 1.49–10.77 0.005 1.80 0.37–8.55 0.450
IL6 2.70 1.06–6.85 0.030 1.93 0.40–9.24 0.400
Homocysteine 1.15 1.04–1.26 0.004 1.07 0.93–1.23 0.320
Vitamin D 0.91 0.87–0.96 0.002 0.88 0.81–0.96 0.007
B2M: beta 2 microglobulin; BMI, body mass index; CI, conﬁdence interval; CysC, cystatin
C; HbA1c, glycated hemoglobin; IL6, interleukin-6; NGAL, neutrophil gelatinase-
associated lipocalin; OR, odds ratio.
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values of the other markers were not considered to be
signiﬁcant.
In this study, the urinary gene expression of BTP
had an AUC of 0.567.
Interaction Among the Biomarkers and
Outcomes Tested
Table 3 shows the results of Spearman’s correlation test
using creatinine values, GFR, and the urinary gene
expression of BTP.
Serum CysC and ACR had signiﬁcant P values with
respect to the worst outcome of renal function in pa-
tients with T2D.
Urinary NGAL showed a positive correlation with
the urinary gene expression of BTP (P ¼ 0.02). We did
not ﬁnd a positive correlation between urinary BTP
and renal outcome but did ﬁnd a tendency for a posi-
tive correlation between urinary BTP and eGFR
(P ¼ 0.06).
The results of the univariate and multivariate
regression models are shown in Table 4, with the
variables as dichotomous outcomes for the presence of
abnormal kidney function. Markers that showed a
positive association in both models are also indicated in
Table 4.
In the univariate model, a positive association was
observed between the values of serum CysC (P ¼ 0.01),Table 3. Correlation of P values of urinary gene expression of BTP
and eGFR with the biomarkers tested in patients with type 2 diabetes
Biomarkers
Variables
Creatinine (mg/dl)
P value
eGFR (ml/min per 1.73 m2)
P value
uBTP
P value
sNGAL (ng/ml) 0.140 0.370 0.310
uNGAL (ng/ml) 0.960 0.740 0.020
sCysC (ng/ml) <0.001 <0.001 0.010
uCysC (ng/ml) 0.680 0.740 0.800
ACR (mg/g) 0.020 0.030 0.250
uBTP 0.090 0.060 –
HbA1c (%) 0.980 0.700 0.280
ACR, albumin-to-creatinine ratio; BTP, beta-trace protein; CysC, cystatin C; eGFR,
estimated glomerular ﬁltration rate; HbA1c: glycated hemoglobin; NGAL, neutrophil
gelatinase-associated lipocalin; Spearman’s correlation test, P < 0.05.
4serum NGAL (P < 0.001), increased age, and male
gender.
All inﬂammatory markers in the univariate model
showed positive associations with the outcome of
abnormal kidney function (eGFR < 60 ml/min per
1.73 m2).
The multivariate model showed a positive associa-
tion between the inﬂammatory markers. Serum 25-OH
vitamin D levels showed a negative association with
worse renal function, with an odds ratio of 0.91 and a
P value of 0.002 in the univariate model and an odds
ratio of 0.81 with P ¼ 0.007 in the multivariate model.
Male gender also showed a strong association with
worse renal function in both models.
The multivariate logistic regression model built with
a backward selection of variables (Table 5) conﬁrmed
the association of male gender, serum CysC, and age
with the outcome of worse kidney function. However,
vitamin D was associated with better kidney function.
DISCUSSION
Patients with diabetes can develop macro- and micro-
vascular complications. The generation of glucose
degradation products and the endothelial damage
triggered by hyperglycemia contribute to a permanent
state of inﬂammation and encourage the persistence of
oxidative stress. Thus, the possibility of jointly eval-
uating previously reported inﬂammatory markers—
interleukin-6, tumor necrosis factor-a, C-reactive pro-
tein, homocysteine, and vitamin D—makes the results
of this study even more interesting.
Urinary Markers
BTP is widely found in body tissues and ﬂuids, and
its elevation has been studied as a marker of reduced
GFR.8 However, BTP presents great variability in
study outcomes due to the differences in measurement
methods and the variations between individuals.9Kidney International Reports (2016) -, -–-
Table 5. Multivariate logistic regression model built with backward
selection of variables with P < 0.05
Variables OR 95% CI P
Age (yr) 1.07 1.00–1.14 0.03
sCysC (ng/ml) 2.04 1.23–3.40 0.005
Vitamin D (ng/ml) 0.89 0.83–0.96 0.003
Male 19.95 4.96–80.22 <0.001
CI, conﬁdence interval; CysC: cystatin C; OR, odds ratio.
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of various markers of the GFR, such as CysC, B2M, and
BTP. Among all of the evaluated markers, BTP showed
the highest intraindividual variability by mass anal-
ysis.9 The RNA extraction and gene ampliﬁcation
process was the most sensitive method, but the amount
of free RNA was small. This problem resulted in an
isolation issue, thereby requiring fast and optimal
processing of the urinary samples.10
Compared with nondiabetic individuals, diabetic
individuals had an association between BTP and renal
dysfunction, with an AUC value of 0.567.
This result differs from previous studies, such as
that by Uehara et al.,11 who found an AUC value of
0.84 when measuring urinary BTP by reaction to latex.
There is a direct association between the urinary
values of NGAL and worse progression of renal function
in T2D without the presence of albuminuria, as shown
by Wu et al.12 Thus, the presence of a larger amount
of this protein before creatinine elevation is an early
marker of tubular dysfunction. The AUC value of uri-
nary NGAL in this experiment was 0.526, which was not
signiﬁcant; however, the increase in urinary NGAL
value and the urinary gene expression of BTP were
positively correlated, according to Spearman’s test.
Matys et al.13 found an AUC value of 0.59 for uri-
nary NGAL in diabetic patients with stable coronary
disease. The authors concluded that in addition to
serum and urinary NGAL, CysC was also not higher
than the eGFR in these patients.12,13
When the other urinary markers were evaluated,
NGAL and CysC did not have the same result as the
ACR but had AUC values of 0.526 and 0.569,
respectively.
An elevated ACR is clinically relevant because it
indicates a loss in glomerular selectivity and/or
reduced tubular reabsorption. In an Indian cohort of
Pima ethnicity, those with microalbuminuria had a 2.1
times higher risk of progression to terminal kidney
disease and were 9.3 times more likely to develop
diabetes than those with normoalbuminuria.14
In this sample, the average ACR was 86.6 mg/g in the
group with HbA1c less than 7% and was 116.5 mg/g
in the group with HbA1c exceeding 7%. Moreover,
there was no division into groups based on ACR, unlikeKidney International Reports (2016) -, -–-the approach used by most of our peers in their
respective analyses. To assess the ACR and its inter-
action with the other markers, we categorized patients
who showed no reduction in GFR by their glucose
levels.
The observed AUC of ACR was 0.660, which was
the best value among the evaluated urinary markers.
This value was positively correlated with creatinine
and the eGFR as expected, and the correlation was a
linear relationship, as indicated by univariate linear
regression.
Serum Biomarkers
HbA1c was tested for its ability to predict renal injury
in accordance with the combined outcome of creatinine
and eGFR, which was estimated using the Modiﬁcation
of Diet in Renal Disease formula. The AUC value was
found to be unsuitable, having a value of 0.568.
However, this study used a cross-sectional analysis,
and the best performance of HbA1c lies in the long-
term monitoring of diabetes.
During a 4-year period, Lee et al.15 analyzed the
effects of glycemic control as determined by HbA1c
values in GFR in T2D. The subjects were divided ac-
cording to HbA1c control; intermediate control was
considered to be approximately 7% to 9%, and the
worst control was considered to be above 9%. Lee et al.
noted that a higher baseline HbA1c was associated
with a greater decline in GFR over the studied period.
The most signiﬁcant outcome was shown in patients
with poor glycemic control and an ACR higher than
300 mg/g.15
CysC and NGAL were positively correlated with
worse eGFR, with AUC values of 0.635 and 0.621,
respectively; in this analysis, these values are only
lower than the value for ACR. In addition, the authors
showed a positive relationship with the combined
endpoint of renal injury assessment, with the univar-
iate logistic regression model showing P ¼ 0.01
and <0.001 for CysC and NGAL, respectively.
CysC showed a positive relationship with renal
injury outcome when there was a choice of variables in
the adjusted multivariate logistic regression model with
P ¼ 0.005. There were also linear relationships with the
continuous values of creatinine and eGFR.
Assal et al.16 assessed the pattern of CysC and uri-
nary NGAL, among other markers, in diabetic subjects
with different levels of eGFR. Subjects were stratiﬁed
according to their baseline ACR, and the CysC values
were higher among those with macroalbuminuria and
increased creatinine values. Nevertheless, the AUC
value in this experiment was 0.727.16
NGAL indicates the elevation of early known prob-
lems in secondary acute kidney injury models—such as5
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tion—as shown in vascular examinations. NGAL has a
good accuracy in predicting early kidney damage in
these situations, but its use in chronic renal injury
models is still under debate.17,18
In a prospective analysis, Chou et al.19 followed a
cohort of diabetic patients stratiﬁed according to GFR
and albuminuria. They noted that those with greater
reduction in GFR during the follow-up period, and
therefore, a greater variation in GFR value, had a
higher serum NGAL value, and NGAL had a positive
correlation with eGFR.19
Inﬂammatory Biomarkers
In our sample, serum homocysteine was related to
kidney dysfunction in the univariate analysis and
linear model built using the continuous values of
creatinine and eGFR. These ﬁndings are consistent with
studies showing deterioration of GFR and elevated
levels of homocysteine in both diabetic and nondia-
betic patients.20,21
However, low vitamin D levels were associated with
worse eGFR and a greater creatinine value in all of the
analyses. Zoppini et al.21 conducted a retrospective
analysis of the serum values of 715 patients with T2D
and found vitamin D deﬁciency in 36.6% of these
diabetic patients. Nevertheless, these patients had more
microvascular complications than those with higher
vitamin D levels.21
The other inﬂammatory markers, C-reactive protein,
interleukin-6, tumor necrosis factor-a, and B2M, did
not show the same behavior as homocysteine and
vitamin D. B2M had a positive association in the uni-
variate logistic regression model using the outcome of
kidney damage.
This study has some limitations. First, this is a cross-
sectional analysis. In a longitudinal follow-up, perhaps
the effect of HbA1c variation in kidney function could
be better evaluated. Another important point to
consider is the variability in urine sample analysis,
particularly with regard to the extraction of RNA and
its ampliﬁcation in the process of gene expression
analysis of urinary BTP. However, our results conﬁrm
that it is possible to assess markers that compare gene
expression in samples of urinary sediment and to un-
derstand the correlation with other markers. In addi-
tion, ACR was found to be a reliable marker in diabetic
patients with poor glycemic control, in the absence of
detected renal dysfunction.
In conclusion, NGAL and serum CysC were posi-
tively associated with the presence of renal dysfunc-
tion and had better performance in terms of ROC
analysis than that of the other markers evaluated in
patients with T2D without kidney dysfunction. NGAL6had an AUC of 0.621, with a sensitivity of 75% and a
speciﬁcity of 53.06%. CysC had an AUC of 0.635, with
a sensitivity of 37.5% and a speciﬁcity of 88%. The
urinary concentrations of these markers did not show
the same performance.
Homocysteine and vitamin D were associated with
the presence of renal dysfunction in all the models
tested. Furthermore, B2M and interleukin-6 showed a
positive correlation with renal dysfunction in the
multivariate logistic regression model.
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